Product Details
| Product Name:
ML239 |
CAS No.:
1378872-36-6 |
| Purity:
99.82% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | ML239 |
| Description | ML239 (CID-49843203) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM. |
| Kinase Assay | ML239 is dissolved in DMSO.Cancer cell lines (CCLs) are plated at a density of 500 cells/well in white opaque tissue-culture-treated Aurora 1536-well MaKO plates in the provider-recommended growth media using a highly automated platform. Compounds (ML239) are added by acoustic transfer using a Labcyte Echo 555. 24 hours after plating. The effects of small molecules (ML239) are measured over a 16-point concentration range (two-fold dilution) in duplicate. DMSO is used at a constant concentration of 0.33%, including vehicle-only control wells. As a surrogate for viability, cellular ATP levels are assessed 72 hours after compound transfer by addition of CellTiterGlo followed by luminescence measurement using a ViewLux Microplate Imager. Duplicates are averaged and luminescence values normalized to vehicle (DMSO) treatment and background (media-only) wells |
| In vitro | ML239 (Compound 7j) serves as a powerful and selective inhibitor targeting breast cancer stem cells, exhibiting an IC50 value of 1.16 μM and demonstrating approximately 24-fold greater selectivity compared to the control cell line. It operates primarily by potentially activating fatty acid desaturase 2 (FADS2), thereby inhibiting the growth of breast cancer stem-like cells. Additionally, ML239 shows cytotoxic effects on NCIH661 cells. Interestingly, the reduction of FADS2 activity, either through direct knockdown or by using the FADS2 inhibitor SC-26196, diminishes the cytotoxicity of ML239 in cancer cell lines (CCLs), suggesting a critical role of FADS2 in ML239's mechanism of action. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (144.26 mM)
Ethanol : 50 mM
|
| Keywords | ML 239 | inhibit | Inhibitor | CID49843203 | ML239 | CID 49843203 | ML-239 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Breast Cancer Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:2682114-54-9
$67.00 / 1mg
-
CAS:115313-22-9
$210.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States